▶Methylphenidateis predicted to increase the risk of a
hypertensive crisis when given withmoclobemide.r
Theoretical
▶Mianserinis predicted to increase the risk of toxicity when
given withmoclobemide. Avoid and for 1 week after stopping
mianserin.rTheoretical→Also seeTABLE 13p. 850
▶Moclobemideis predicted to increase the effects ofmonoamine-
oxidase B inhibitors(rasagiline, selegiline). Avoid.r
Theoretical→Also seeTABLE 13p. 850
▶Moclobemideis predicted to increase the risk of side-effects
when given withmonoamine-oxidase B inhibitors(safinamide).
Avoid and for 1 week after stoppingsafinamide.r
Theoretical→Also seeTABLE 13p. 850
▶Opicaponeis predicted to increase the risk of elevated blood
pressure when given withmoclobemide. Avoid.r
Theoretical
▶Moclobemideincreases the risk of side-effects when given
withphenothiazines(levomepromazine).oStudy
▶Reboxetineis predicted to increase the risk of a hypertensive
crisis when given withmoclobemide. Avoid.rTheoretical
▶Moclobemidemoderately increases the exposure torizatriptan.
Avoid.oStudy→Also seeTABLE 13p. 850
▶Moclobemidemoderately increases the exposure to
sumatriptan. Avoid.oStudy→Also seeTABLE 13p. 850
▶Moclobemideis predicted to increase the risk of a hypertensive
crisis when given withsympathomimetics, vasoconstrictor
(ephedrine, isometheptene, phenylephrine, pseudoephedrine).
Avoid.rStudy
▶Tricyclic antidepressantsare predicted to increase the risk of
severe toxic reaction when given withmoclobemide. Avoid.
rTheoretical→Also seeTABLE 13p. 850
▶Moclobemideslightly increases the exposure tozolmitriptan.
Adjustzolmitriptandose,p. 292.oStudy→Also see
TABLE 13p. 850
Modafinil
▶Antiepileptics(carbamazepine, phenobarbital, primidone)are
predicted to decrease the exposure tomodafinil.n
Theoretical
▶Antiepileptics(fosphenytoin, phenytoin)are predicted to
decrease the exposure tomodafinilandmodafinilis predicted
to increase the concentration ofantiepileptics(fosphenytoin,
phenytoin). Monitor concentration and adjust dose.o
Theoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tomodafinil.nTheoretical
▶Modafinilis predicted to decrease the exposure tobosutinib.
Avoid.rTheoretical
▶Cobicistatis predicted to increase the exposure tomodafinil.
nTheoretical
▶Modafinilis predicted to decrease the efficacy ofcombined
hormonal contraceptives. For FSRH guidance, see
Contraceptives, interactionsp. 497.rStudy
▶Modafinilis predicted to decrease the efficacy ofdesogestrel.
For FSRH guidance, seeContraceptives, interactionsp. 497.
rTheoretical
▶Modafinilis predicted to decrease the exposure toelbasvir.
Avoid.qTheoretical
▶Modafinilis predicted to decrease the efficacy ofetonogestrel.
For FSRH guidance, seeContraceptives, interactionsp. 497.
rTheoretical
▶Modafinilis predicted to decrease the exposure tograzoprevir.
Avoid.qTheoretical
▶HIV-protease inhibitorsare predicted to increase the exposure
tomodafinil.nTheoretical
▶Modafinilis predicted to decrease the effects ofhormone
replacement therapy.oAnecdotal
▶Idelalisibis predicted to increase the exposure tomodafinil.
nTheoretical
▶Modafinilis predicted to decrease the efficacy of
levonorgestrel. For FSRH guidance, seeContraceptives,
interactionsp. 497.rTheoretical
▶Macrolides(clarithromycin)are predicted to increase the
exposure tomodafinil.nTheoretical
▶Modafinilis predicted to decrease the efficacy of
norethisterone. For FSRH guidance, seeContraceptives,
interactionsp. 497.rAnecdotal
▶Rifampicinis predicted to decrease the exposure tomodafinil.
oTheoretical
▶Modafinildecreases the efficacy ofulipristal. For FSRH
guidance, seeContraceptives, interactionsp. 497.r
Anecdotal
▶Modafinilis predicted to decrease the concentration of
voxilaprevir. Avoid.rTheoretical
Mometasone→see corticosteroids
Monoamine-oxidase A and B inhibitors, irreversible→see
TABLE 8p. 848 (hypotension),TABLE 13p. 850 (serotonin syndrome)
isocarboxazid.phenelzine.tranylcypromine..FOOD AND LIFESTYLEPotentially life-threatening hypertensive
crisis can develop in those taking MAOIs who eat tyramine-
rich food (such as mature cheese, salami, pickled herring,
Bovril®,Oxo®,Marmite®or any similar meat or yeast extract
or fermented soya bean extract, and some beers, lagers or
wines) or foods containing dopa (such as broad bean
pods). Avoid tyramine-rich or dopa-rich food or drinks with,
or for 2 to 3 weeks after stopping, the MAOI.
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the effects ofalpha blockers(indoramin).
Avoid.rTheoretical→Also seeTABLE 8p. 848
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the risk of a hypertensive crisis when
given withamfetamines. Avoid and for 14 days after stopping
the MAOI.rAnecdotal→Also seeTABLE 13p. 850
▶Antiepileptics(carbamazepine)are predicted to increase the risk
of severe toxic reaction when given withmonoamine-oxidase A
and B inhibitors, irreversible. Avoid and for 14 days after
stopping the MAOI.rTheoretical
▶Antiepileptics(phenobarbital, primidone)are predicted to
increase the effects ofmonoamine-oxidase A and B inhibitors,
irreversible.rTheoretical
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the risk of antimuscarinic side-effects
when given withantihistamines, non-sedating. Avoid.r
Theoretical
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the risk of antimuscarinic side-effects
when given withantihistamines, sedating. Avoid.r
Theoretical
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the risk of side-effects when given with
atomoxetine. Avoid and for 2 weeks after stopping the MAOI.
rTheoretical
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the risk of cardiovascular side-effects
when given withbeta 2 agonists.oAnecdotal
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the risk of severe hypertension when
given withbupropion. Avoid and for 14 days after stopping the
MAOI.rTheoretical→Also seeTABLE 13p. 850
▶Buspironeis predicted to increase the risk of elevated blood
pressure when given withmonoamine-oxidase A and B
inhibitors, irreversible. Avoid.rAnecdotal→Also see
TABLE 13p. 850
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the effects ofdoxapram.o
Theoretical
▶Entacaponeis predicted to increase the risk of elevated blood
pressure when given withmonoamine-oxidase A and B
inhibitors, irreversible. Avoid.rTheoretical
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to decrease the antihypertensive effects of
guanethidine. Avoid and for 14 days after stopping the MAOI.
rTheoretical→Also seeTABLE 8p. 848
▶Levodopaincreases the risk of a hypertensive crisis when
given withmonoamine-oxidase A and B inhibitors, irreversible.
Avoid and for 14 days after stopping the MAOI.rStudy→
Also seeTABLE 8p. 848BNFC 2018 – 2019 Moclobemide—Monoamine-oxidase A and B inhibitors, irreversible 957
Interactions|Appendix 1A1